Ratio Therapeutics Inc. Monday announced partnership with Novartis Pharma AG, a unit of Novartis AG (NVS) to develop a ...

Ratio Therapeutics entered today into an exclusive worldwide license and collaboration agreement with Novartis (NVS) Pharma AG, a subsidiary of ...

Ratio to receive upfront, and potential milestones and tiered royalty payments BOSTON, Nov. 18, 2024 /PRNewswire/ -- Ratio Therapeutics Inc. (Ratio), a pharmaceutical ...

UBS has recently reduced Royalty Pharma plc (RPRX) stock to Neutral rating, as announced on June 3, 2024, according to Finviz. Earlier, on June 14, 2022, UBS had resumed the stock to Buy, setting a ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

In turn, Ratio is in line to receive combined upfront and possible milestone payments up to $745 million, plus royalty ...

The US Food and Drug Administration (FDA) has approved Syndax Pharmaceuticals' Revuforj (revumenib) for treating relapsed or ...

Subsequently, in October of 2024, we received $15 million in cash from XOMA for the rights to half of our potential milestone and royalty payments related to ... parts and the potential for pressure ...

Under the terms of the agreement, Ratio will receive combined upfront and potential milestone payments up to $745m, and is eligible to receive tiered royalty payments ... collaboration agreement with ...

Metalla Royalty & Streaming Ltd. (NYSEMKT:MTA – Free Report) – Equities researchers at National Bank Financial raised their FY2026 EPS estimates for shares of Metalla Royalty & Streaming in a note ...

Royalty payments made by Indian listed companies to their related parties (RPs) have more than doubled in the last decade, rising from INR 4,955 crore in FY14 to INR 10,779 crore in FY23, according to ...

Keymed Biosciences has licensed global rights for CM336, excluding Greater China, to Platina Medicines in a deal worth up to ...